Browse News

Found 2,731 articles

• 

  When Experience Becomes a Barrier: Ageism at Work

  3/23/2023

  Ageism, or discrimination against an individual based on their age, is a common barrier many older individuals face in the workplace. Fortunately, there are steps that can be taken to mitigate this discrimination.

• Entera Bio Regains Compliance with Nasdaq Listing Requirements

  3/23/2023

  Entera Bio Ltd. announced today that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on March 23, 2023, informing Entera that it has regained compliance with the minimum bid price requirement under NASDAQ Listing Rule 5550(a)(2) for continued listing on The NASDAQ Capital Market.

• Daré Bioscience to Host Full-year 2022 Financial Results and Company Update Conference Call and Webcast on March 30, 2023

  3/23/2023

  Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, March 30, 2023, to review its financial results for the year ended December 31, 2022 and to provide a Company update.

• Nuritas Artificial Intelligence Discovers Plant-Sourced Peptides with Dramatic Effects on Muscle Strength and Recovery

  3/21/2023

  Nuritas’ second clinical offers the most effective solution ever discovered for muscle health

• Acer Therapeutics Announces Topline Results from ACER-801 (Osanetant) Phase 2a TrialACER-801 safe and well-tolerated but did not achieve statistically significant decrease in frequency or severity of hot flashes in postmenopausal women

  3/17/2023

  Acer Therapeutics Inc. (Nasdaq: ACER) today announced that topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant).

• New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer

  3/15/2023

  Verastem Oncology today announced the launch of Let’s Talk About LGSOC, a new initiative that calls attention to low-grade serous ovarian cancer (LGSOC).

• Results from Astellas' Pivotal Phase 3 SKYLIGHT 1™ Study of Fezolinetant for Vasomotor Symptoms Due to Menopause Published in The Lancet

  3/13/2023

  Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") today announced The Lancet published detailed results from the pivotal Phase 3 SKYLIGHT 1™ study of fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause.

• 

  Bayer Plans to Double Down on US Pharma R&D in 2023

  3/9/2023

  Bayer plans to substantially increase investment in U.S.-based pharmaceutical R&D, earmarking $1 billion to invest stateside in 2023.

• Sermonix Pharmaceuticals Announces Initiation of Phase 3 ELAINE-3 Study of Lasofoxifene Plus Abemaciclib in Pre- and Post-Menopausal Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer

  3/9/2023

  Sermonix anticipates dosing the first patient in first half of 2023.

• SpringWorks Therapeutics Announces New England Journal of Medicine Publication of Phase 3 DeFi Trial Evaluating Nirogacestat in Adults with Desmoid Tumors

  3/8/2023

  SpringWorks Therapeutics, Inc. announced today that data from the Phase 3 DeFi trial of nirogacestat, an investigational oral gamma secretase inhibitor, in adult patients with progressing desmoid tumors, were published in the New England Journal of Medicine (NEJM).

• Sermonix’s Lasofoxifene Improves Vaginal/Vulvar Symptoms Relative to Fulvestrant in ELAINE 1 Study of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2- Breast Cancer and an ESR1 Mutation

  3/6/2023

  Sermonix Pharmaceuticals Inc. today announced that its lead drug candidate, lasofoxifene, improved vaginal/vulvar symptoms while fulvestrant worsened them in a study of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation.

• Aptorum Group Announces Completion of Pre-IND Discussions with US FDA on its ALS-4, a First-in-Class Small Molecule Drug Targeting Methicillin Resistant Staphylococcus Aureus

  3/3/2023

  Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of the Pre-IND discussions with the US Food and Drug Administration (“US FDA”).

• Aptorum Group Announces Completion of End of Phase 1 (EOP1) Meeting with US FDA on its SACT-1, a Repurposed Small Molecule Drug Targeting Neuroblastoma

  3/3/2023

  Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the completion of an end of Phase 1 (EOP1) meeting with the US Food and Drug Administration (“US FDA”). SACT-1 is a repurposed small molecule drug formulated in oral suspension targeting neuroblastoma in pediatric patients.

• Daré Bioscience to Present at the 35th Annual Roth Conference

  3/1/2023

  Daré Bioscience, Inc. (NASDAQ: DARE ), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, the company’s President and CEO, will present at the 35th Annual Roth Conference, being held March 12-14, 2023 in Laguna Niguel, CA.

• Daré Bioscience Announces Start of a Phase 1 Study for its Potential First-in-Category Treatment for Primary Dysmenorrhea, DARE-PDM1

  2/22/2023

  Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced the start of a Phase 1 study evaluating its development program targeted at treating primary dysmenorrhea by delivering the active pharmaceutical ingredient diclofenac, a nonsteroidal anti-inflammatory drug (NSAID), in a novel way.

• Astellas Provides Update on Fezolinetant New Drug Application in U.S.

  2/19/2023

  Astellas Pharma Inc. announced the U.S. Food and Drug Administration notified the company that it is extending the original priority review Prescription Drug User Fee Act goal date for fezolinetant, an investigational agent for the treatment of moderate to severe vasomotor symptoms due to menopause.

• Entera Bio Announces FDA’s Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis

  2/15/2023

  Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today announced that a Type D meeting protocol review has been accepted by the U.S. Food and Drug Administration (FDA) to provide responses by March 30th, 2023.

• NervGen Pharma Announces Completion of Dosing of All Subjects in Phase 1 Clinical Trial of Proprietary Drug Candidate NVG-291

  2/14/2023

  NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing innovative solutions for the treatment of nervous system damage, announced that all subjects (male, premenopausal and post-menopausal females) in the Phase 1 clinical trial

• Acer Therapeutics Announces Full Enrollment of Phase 2a Trial of ACER-801 (Osanetant) for Treatment of Moderate to Severe Vasomotor Symptoms Associated with MenopauseTopline trial results expected mid-March 2023

  2/13/2023

  Acer Therapeutics Inc. (Nasdaq: ACER) today announced full enrollment of its Phase 2a proof of concept trial of ACER-801 (osanetant), a novel, non-hormonal, neurokinin 3 receptor (NK3R) antagonist, being investigated as a potential treatment option for moderate to severe Vasomotor Symptoms (VMS) associated with menopause.

• Madorra announces publication of positive 12-week and 12-month Pilot 1 Randomized Controlled Trial Results

  2/9/2023

  Madorra announces publication of positive Pilot 1 randomized controlled trial results for the company's non-invasive, home-use device for women experiencing moderate to severe vulvovaginal atrophy, a component of genitourinary syndrome of menopause.